Cristea. Cătălina-Diana CD; Radu. Mihai M; Toboc. Ani A; Stan. Cristina C; David. Victor...
Scientists created a very sensitive urine test that can spot tiny amounts of growth‑hormone‑releasing peptides like sermorelin (GRF‑1‑29). It can detect as little as 0.2 ng/mL, which is far lower than most everyday tests, and it meets anti‑doping standards. For biohackers, this means the test can catch even low‑dose use, but the study doesn’t give any new tips on how to use the peptide safely or effectively.
In rats that ate very little protein right after weaning, their natural growth‑hormone bursts stayed low even after they later ate a normal diet. When these rats were given the peptide GRF‑1‑29, their growth‑hormone levels spiked much higher than normal rats. Their insulin response to sugar was also dramatically weaker, even though other markers looked okay.
Corbitt. J J; Hagerty. T T; Fernandez. E E; Morgan. W W WW; Strong. R R
In a cell‑culture study, the peptide PACAP38 was shown to raise the messenger RNA for tyrosine hydroxylase (the enzyme that starts dopamine and norepinephrine production) more strongly and for a longer time than the related peptide VIP. This effect depends on activating a protein‑kinase C (PKC) pathway, while VIP does not trigger PKC. The findings come from rat PC12 cells, not humans, so they are not directly actionable for personal use.
Cunha-Reis. Diana D; Aidil-Carvalho. Maria de Fatima Mde F; Ribeiro. Joaquim A JA
The study shows that a natural brain chemical called VIP normally blocks certain types of learning‑related brain changes (LTD and depotentiation) by acting on VPAC1 receptors. When a drug that blocks these VPAC1 receptors (the peptide GRF‑1‑29) is added, those brain changes become stronger, suggesting that reducing VIP signaling could boost learning flexibility. The effect also depends on GABA, another brain messenger.
Gaudin. P P; Couvineau. A A; Maoret. J J JJ; Rouyer-Fessard. C C; Laburthe. M M
Scientists made a stable cell line that shows how the human VIP1 receptor works. They measured how tightly VIP and similar peptides bind, how they trigger cAMP signals, and how the receptor behaves after long‑term exposure. One of the peptides tested was a modified version of GRF‑1‑29, which turned out to bind the VIP receptor only weakly and acted as an antagonist, not as an activator.
Scientists found that pig placenta contains a substance that looks like the growth‑hormone‑releasing factor (GRF) and can make pituitary cells release more growth hormone in a dish. The effect goes away when a GRF blocker is added, showing it works through the usual GRF pathway.
In a lab study using pig pituitary cells, researchers found that the brain peptide neuropeptide‑Y (NPY) does not change the release of the reproductive hormone LH, but it can raise the amount of growth hormone (GH) that the cells release on its own. When combined with a GH‑releasing factor, low amounts of NPY actually dampened the GH boost, while a higher amount of NPY helped the GH‑releasing factor work a bit better. These effects were seen only in isolated cells, not in whole animals.
Estévez. M D MD; Botana. M A MA; Arnáez. E E; Vieytes. M R MR; Botana. L M LM
The study shows that the peptide GRF‑1‑29 can make rat mast cells release histamine, especially at body temperature, and this effect can be blocked by certain chemicals. The findings are from rat cells and don’t directly tell us what happens in humans.
Timms. Mark M; Ganio. Katherine K; Forbes. Grace G; Bailey. Simon S; Steel. Rohan R
The paper describes a super‑sensitive test that can spot the performance‑enhancing peptide CJC‑1295 in horse blood, even though the drug sticks to plasma proteins and hides from usual mass‑spec methods. It shows the peptide stays in the bloodstream much longer because of this binding, and the new assay can detect it at very low levels.
Jessup. Stacy K SK; Malow. Beth A BA; Symons. Kathleen V KV; Barkan. Ariel L AL
Blocking the body's natural growth‑hormone‑releasing hormone (GHRH) stops the usual night‑time spike in growth hormone, but it doesn't change how much deep (slow‑wave) sleep you get. In other words, the hormone that triggers growth hormone release isn’t needed to create deep sleep.
Youn. Yu Seok YS; Na. Dong Hee DH; Yoo. Sun Dong SD; Song. Soo-Chang SC; Lee. Kang Choon KC
Researchers created a simple lab test that can separate and identify all the different versions of a PEG‑attached growth hormone‑releasing factor (GRF‑1‑29) peptide. By looking at how the PEG is attached, they can tell each version apart, which will help future work on how stable and effective each version is.
In horses, giving recombinant growth hormone (eST) either every day or every other day raised blood sugar, insulin, and fatty acids while lowering waste nitrogen, but daily shots boosted IGF‑1 faster. Giving the hormone more than once a day (twice or four times) made IGF‑1 and insulin rise even more, though the waste nitrogen drop was the same no matter how often it was injected.
Liu. Q Q; Lei. T T; Liu. K K; Lin. W W; Adams. E F EF
In lab-grown human pituitary cells, the peptide hexarelin sharply increased growth hormone release by activating a PKC pathway, while the related peptide GRF‑1‑29 (a GHRH fragment) didn’t stop hexarelin but did block the normal GHRH effect. Hexarelin didn’t raise cAMP on its own but made GHRH’s cAMP‑driven boost bigger, showing the two peptides can interact.
Piquet. G G; Gatti. M M; Barbero. L L; Traversa. S S; Caccia. P P; Esposito. P P
The researchers figured out how to make a bigger batch of a PEG‑linked version of the growth‑hormone‑releasing factor (GRF‑1‑29) and keep it pure using a single chromatography step. They went from 100 mg to about 3 g without losing yield or quality, showing the process can be scaled up reliably.
Woda. Craig B CB; Halaihel. Nabil N; Wilson. Paul V PV; Haramati. Aviad A; Levi. Moshe M; Mulroney....
In young rats, growth hormone (boosted by the peptide GRF‑1‑29) makes the kidneys re‑absorb more phosphate by increasing a transporter called NaPi‑2. When GH is blocked, phosphate handling looks like that of adult rats. Giving back the peptide restores the high phosphate re‑absorption seen in juveniles.
Glavaski-Joksimovic. A A; Jeftinija. K K; Jeremic. A A; Anderson. L L LL; Jeftinija. S S
The study shows that the growth hormone secretagogue L‑692,585 (L‑585) can trigger a rise in calcium inside pituitary cells and cause those cells to release more growth hormone. It works through a different receptor than the usual GHRH receptor and needs calcium channels and internal calcium stores to do its job. While this confirms how such secretagogues act, it doesn’t give dosing tips or direct guidance for everyday use.
Swanchara. K W KW; Armstrong. J D JD; Britt. J H JH
In a pig study, vaccinating young females against the hormone‑releasing peptide GRF‑1‑29 lowered their growth hormone, IGF‑1 and body weight, made them fatter, and changed some aspects of their reproductive organs, but did not change when they hit puberty. Early‑life blocking of GRF also reduced the number of eggs released later on.
Geris. K L KL; Hickey. G J GJ; Berghman. L R LR; Visser. T J TJ; Kühn. E R ER; Darras. V M VM
In chickens, the synthetic compound L-692,429 quickly boosts growth hormone (GH) levels by acting both on the pituitary gland and by lowering a brain hormone (TRH) that normally holds GH back. It also raises stress hormone (corticosterone) but doesn’t change thyroid hormones. While the study shows the compound works in birds, it doesn’t tell us how it behaves in people.
Yajima. Y Y; Akita. Y Y; Saito. T T; Kawashima. S S
In a lab study with rat pituitary cells, the peptide VIP caused a key signaling protein (Gsα) to leave the cell membrane and be broken down over time. This shift was blocked by a specific VIP‑receptor blocker (GRF‑1‑29) and also happened with a related peptide, PACAP. The effect depended on the amount of VIP used.
Garrido. E E; Delgado. M M; Martínez. C C; Gomariz. R P RP; De la Fuente. M M
In a lab study on rat immune cells, the peptide PACAP38 was found to make both lymphocytes and macrophages stickier, but it made macrophages move more while slowing down lymphocytes. The peptide works through different receptors and signaling pathways in the two cell types, involving protein kinase C in macrophages and cAMP in lymphocytes.